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Abstract
Progress has been made in the control or elimination of tropical diseases, with a significant reduction of incidence. However,
there is a risk of re-emergence if the factors fueling transmission are not dealt with. Although it is essential to understand these
underlying factors for each disease, asymptomatic carriers are a common element that may promote resurgence; their impact in
terms of proportion in the population and role in transmission needs to be determined. In this paper, we review the current
evidence on whether or not to treat asymptomatic carriers given the relevance of their role in the transmission of a specific
disease, the efficacy and toxicity of existing drugs, the Public Health interest, and the benefit at an individual level, for example,
in Chagas disease, to prevent irreversible organ damage. In the absence of other control tools such as vaccines, there is a need for
safer drugs with good risk/benefit profiles in order to change the paradigm so that it addresses the complete infectious process
beyond manifest disease to include treatment of non-symptomatic infected persons.
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Introduction
The term ‘symbiosis’ sensu lato encompasses an extraordi-
nary range of relationships between living organisms deter-
mined by co-evolution, ranging from being beneficial for both
(‘mutualism’) to situations where one kills the other (‘preda-
tion’). Within this range of possibilities is ‘parasitism’ (from
Greek, ‘para’ = next to, ‘sitos’ = to seat1). Parasitism is a long-
term relationship between host and parasite that lasts until the
symbiosis reaches an imbalance, eventually resulting in host
or parasite death. In addition, the sooner a parasite kills the
host, the worse the outcome for the parasite’s life cycle ‘goal’;
thus, it needs mechanisms to circumvent this limitation. To
enable the parasite to survive in the host the parasite requires
three things: nutrition, shelter from a hostile environment, and
time to reach reproductive maturity and/or to allow vectors an
opportunity for transmission, in other words, to ensure that the
parasites are perpetuated. Once the parasite ‘loses’ its host,
parasite survival becomes challenging, although there are var-
ious mechanisms to overcome this. At least two key questions
1 In Ancient Greece, offerings and sacrifices to the gods were performed by
the priest at an altar, next to it rich and prominent citizens sat around eating the
remaining food; they were called ‘parasites’.
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emerge from this kind of relationship: First, how the shared
natural history of the parasite and the host ensures a long
relationship, and second, why parasitism does not necessarily
end in disease.
In parasitic diseases, survival strategies developed by hel-
minths are different to those evolved by protozoa, although
both follow a basic pattern. Figure 1 summarizes and com-
pares the routes used by the parasites mentioned in this article
to evade the immune response and the ways the host is able to
eliminate them. All these parasites can avoid the immune re-
sponse by varying their antigens (not shown in the figure), and
they are able to evade innate immune response by following
different strategies. The host is able to eliminate parasites
through an adaptive immune response that involves antigenic
presentation by DCs and macrophages, and the selection and
activation of specific T and B cells. Although this route is
common for all these parasites, the effector mechanisms
against protozoa involve the development of a specific Th1
response, which induces the microbicide activity of macro-
phages and the cytotoxic activity of CD8+ T cells. In the case
of filaria, the protective response is associated with the pro-
duction of different isotypes of specific antibodies, depending
on the development of an effective type Th2 immune
response.
Infection is the first contact between the parasite and its
host; the host may kill the parasite due to innate and/or ac-
quired immunity, or the parasite may survive due to an effi-
cient mechanism that evades the host response. If the parasite
survives, an intriguing dynamic relationship between host and
parasite may result; when in balance, the host becomes an
‘asymptomatic carrier’, and when out of balance, the result
is disease. Disease manifestation is preceded by a variable
period of time known as a pre-patent or incubation period,
corresponding to the time required by the parasite to subvert
host immunity. Due to co-evolution, it is very common in
some parasitic diseases for the number of patients to be low
compared with the large number of people with asymptomatic
infection (note: in general, an infected person who is asymp-
tomatic is not necessarily a patient).
Figure 2 summarizes the process of infection, resulting in
an asymptomatic condition or clinically diagnosable disease.
Parasite mechanisms to avoid host immune response
Parasites have developed different mechanisms to manipulate
host immunity to ensure appropriate conditions for multipli-
cation in the chronic infection stage. Cellular recognition, ac-
tivation, and regulation of innate and adaptive host immune
responses are altered to allow parasite persistence in host tis-
sues for, at the very least, long enough to multiply and reach
the numbers necessary for successful transmission. In fact,
many vector borne parasites establish long-lasting chronic in-
fections in order to maximize the probability of transmission
[1].
It is well recognized that helminths induce host immune
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Fig. 1 Comparison of the different immune responses to the parasites mentioned in this article
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and, therefore, their evasion mechanisms are different.
Intracellular infection is a common mechanism in protozoa that
prevents activation of the complement system, together with
subverting the T cell response and inhibiting signalling path-
ways such as NF-kB or the expression of MHC molecules. In
helminths, frequently, the release of immunomodulatory mole-
cules, e.g. antiinflammatory or host immunosuppressive cyto-
kines homologues, directly suppresses the host immune re-
sponse. One strategy shared by protozoa and helminths to
evade the host immune response is antigenic variation [2].
Parasites studied in this review
This review focusses on five insect-borne tropical diseases:
Chagas disease, human African trypanosomiasis (HAT), leish-
maniasis, filariasis, and malaria, all caused by parasites with
different survival mechanisms in the host, leading to very dif-
ferent consequences for epidemiology, and with heterogeneous
needs in terms of chemotherapy. Insights into the role of asymp-
tomatic patients arose from a 1-day conference conducted by
DNDi in Geneva on 19 February 2019, entitled ‘Asymptomatic
infections, implications for drug development’, aiming to better
understand the needs for drug discovery and development, and
how to implement products in the DNDi portfolio. DNDi has
targeted neglected tropical diseases (NTDs) and malaria by
making therapies available through registration in endemic
countries and/or developing better patient-adapted treatments
through improvement in formulations or drug combinations.
Over the longer term, DNDi has defined and refined target
product profiles to guide de novo design of tailor-made, pa-
tient-adapted, oral therapies, aiming for short treatment duration
and addressing all needs in disease populations. A number of
low-cost, relatively short-duration therapies have been made
available through the work of DNDi and partners. These in-
clude fixed dose combinations of artesunate + mefloquine
(ASMQ) and artesunate + amodiaquine (ASAQ) for both adult
and paediatric populations with malaria; a combination treat-
ment of nifurtimox eflornithine therapy (NECT) for use in hos-
pital settings, and oral treatments fexinidazole and acoziborole
(a potential one-dose, oral drug with a good safety profile
currently in advanced phase 3 clinical trials) for treatment of
HAT; therapies for Indian, African, and South American leish-
maniasis, and other clinical manifestations of leishmaniasis,
such as post-kala-azar dermal leishmaniasis and severe forms
of leishmaniasis with HIV coinfection; and a paediatric formu-
lation of benznidazole for cases of congenital transmission of
Chagas disease. Some of these treatments may be applicable for
the treatment of asymptomatic individuals infected with para-
sites. In addition, innovative oral therapies are in development
to meet the duration, efficacy, and tolerability gaps of currently
available treatments and to treat human reservoirs of disease (an
overview of the DNDi portfolio and approaches to new thera-
pies is available at www.DNDi.org). In line with DNDi’s
strategy to address patient needs and potential reservoirs of
new disease or outbreaks in order to control or eliminate
NTDs, this review addresses the potential challenges to
disease elimination from individuals with asymptomatic
infections who, although not presenting clinical symptoms,
may act as reservoirs for infection and foci for new disease
outbreaks. The characteristics of asymptomatic infections and
their potential for disease generation are discussed below and
will be examined in the context of the challenges for disease
elimination or control.
Chagas disease
More than six million people are estimated to be infected with
the causative agent of Chagas disease, Trypanosoma cruzi
(T. cruzi) [3]. Chagas disease presents in two phases, the main
clinical characteristic being the lack of symptoms for the acute
phase and, if it appears, non-specific symptoms for the chronic
phase [4]. Around 95% of those in the acute phase are asymp-
tomatic carriers. This is clinically relevant, because without
diagnosis and treatment, people in the acute phase enter into a
chronic phase, after which, in the absence of treatment, about
70% will have parasites circulating in their blood and tissues
for the rest of their lives without evidence of organ involve-
ment [4].
Host-parasite interactions that lead to such a broad clinical



















Fig. 2 Typical evolution of the infection/disease process resulting in an asymptomatic condition (yellow) or clinically diagnosable disease (red)
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discovery of Chagas disease. The presence and polymorphism
of T. cruzi has been considered to be key to this, but up to now,
correlations between the pathogenicity, tissue-tropism, or
drug-susceptibility [5] of specific T. cruzi strains or distinct
typing units have yet to be confirmed [6].
Approximately five million people globally are asymptom-
atic T. cruzi carriers, which is highly significant in terms of
individual and public health. From an individual health man-
agement point of view, people with asymptomatic infection
(in the ‘indeterminate clinical form’) are those in which there
is evidence of T. cruzi infection, but no evidence of organ
damage (mainly cardiological or digestive), assessed by (1)
non-specific symptoms and (2) low sensitivity tests to detect
early organ damage, such as electrocardiogram, chest X-ray,
and barium swallow and enema. Even without evidence of
organ damage, it is possible that a silent progressive
physiopathogenic process has begun, due to the presence of
parasites circulating in the blood and those infected tissues
where replication takes place [7]. The presence of parasites
in blood or tissues can induce damage directly or by inducing
microvascular alterations and/or a specific immune response
that produces an imbalance in favour of the development of
pathogenesis [8].
Lack of evidence of damage does not mean a lack of pro-
gression of organ damage, but rather a lack of accurate tools to
detect the damage early, delaying diagnosis, and therapeutic
options for patients. However, with the diagnostic tools cur-
rently available, it is not possible to predict which people with
an asymptomatic infection will develop Chagas disease in the
future.
Asymptomatic people may contribute to transmission in
endemic countries primarily not only through vector transmis-
sion but also throughmother to child transmission, transfusion
of uncontrolled blood and blood products, and organ trans-
plant. Thus, early diagnosis and treatment of asymptomatic
carriers of T. cruzi is an individual and public health measure
that contributes to disease control. The higher the burden of
disease in a population in terms of parasitaemia (‘populational
parasitaemia’), the greater the need for treatment. Control
measures adapted to local scenarios are essential for reducing
the number of new cases.
There is currently enough evidence to recommend treat-
ment in people under 18 years old, andwomen of reproductive
age [9], and there is increasing evidence of the value of
treating infected people and people with mild chronic disease
(in all cases without contraindication) [10–12].
There are limitations to scaling up treatment, such as health
workers’ reluctance to prescribe treatment due to the safety
profile, and the lack of clear evidence about the clinical benefit
of treating asymptomatic adults. Accepted drugs to treat
T. cruzi infection (benznidazole and nifurtimox) eliminate or
reduce parasitaemia but have a suspension rate of around 20%
due to poorly tolerated side effects [13, 14].
Inadequate production, and consequently distribution, in-
creasing the barriers to easy and continuous access to treat-
ment [15, 16], is in part due to a random forecast of drug
needs.
Nevertheless, in public health terms, diagnosis and treat-
ment of asymptomatic people is a method of primary preven-
tion for congenital and vectorial transmission and of second-
ary prevention in terms of morbimortality. In addition, admin-
istering a drug that tackles chronic infectious Chagas disease
has positive effects in terms of well-being, a factor which has
not been widely measured up to now; psychological factors
and perceptions, even if they are described in this population,
have not been studied in terms of the impact on quality of life.
The first research need emerging from the discussion above
is better diagnosis and classification of people with T. cruzi
infection. To do this, more accurate tests to determine organ
damage early should be available in countries with a high
burden of Chagas disease [17]. Discovery and development
of molecular biomarkers of early cardiological and digestive
damage, as well as prognostic biomarkers, would be useful
tools to address this need [18, 19].
To control transmission dynamics due to asymptomatic
infections, and to contribute to reducing their numbers in tra-
ditionally and newly endemic areas, more accurate knowledge
of the epidemiological situation in each country is needed.
Seroepidemiological studies that support more efficient local
surveillance systems are necessary to better establish needs
and prioritize control measures. Updated local guidelines for
case management of individuals infected with T. cruzi that are
adapted to each context are also necessary [16], and harmoni-
zation between currently existing guidelines would facilitate
more comprehensive healthcare.
In terms of research, even though in the last decade new
drugs were tested in the hope of increasing treatment options
for patients with T. cruzi infection [11, 12], there remains an
urgent need to develop new drugs and new regimens and/or
combinations of existing drugs. Drugs and/or drug combina-
tions with good efficacy and, importantly, a better safety pro-
file may increase treatment access for people with asymptom-
atic T. cruzi infection, facilitating better case management at
the individual level, and modifying transmission dynamics by
reducing population parasitemia. In order to complete cost-
effectiveness studies, there is a need for more data, as the
clinical impact and quality of life data currently available for
asymptomatic people who have received diagnosis and treat-
ment is inadequate.
These needs for Chagas disease were summarized and pre-
sented to regulatory regional and global health institutions
after agreement between researchers, physicians (at individual
and institutional level) and communities in the form of the
Santa Cruz letter [20]. Three out of the four measures pro-
posed are in line with the perspectives highlighted in this
manuscript.
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The first is to expand access to diagnosis and treatment of
the disease within the framework of health systems. For
asymptomatic people, this means increasing coverage to two
thirds of people with T. cruzi infection; as a result of imple-
mentation, there will be a reduction in the number of new
cases and, consequently, a reduction in the burden of the dis-
ease, contributing to disease control.
The second is to increase investment in research and devel-
opment, in alignment with the Sustainable Development
Goals, to obtain new, safer, and more effective therapeutic
tools. This measure supports not only the strategy to discover
and produce new drugs but also the need to obtain new diag-
nosis and prognosis tools that better define individual risk of
developing organ damage.
The third, to improve the surveillance of Chagas disease by
establishing compulsory reporting of chronic cases and their
complications in the general population, addressed the need
for a better surveillance system to support the design of more
accurate public health strategies to control T. cruzi in the group
with the highest burden of infection.
Human African trypanosomiasis
HAT is caused by two species of the kinetoplastid protozoan
parasite Trypanosoma brucei: T. b. gambiense (West and
Central Africa) and T. b. rhodesiense (East Africa) and is
transmitted to humans by tsetse flies. Asymptomatic infec-
tions may exist for both forms of HAT but latent infections
lasting for decades are only documented for Trypanosoma
brucei gambiense (T. b. gambiense) [21, 22]. In contrast to
animal trypanosomiasis, investigations into the underlying
mechanisms of trypanotolerance in HAT are rare. Few studies
have investigated the immune response in individuals with
detectable antitrypanosome antibodies but without detectable
parasites in blood or lymph node aspirate. In these individuals,
elevated levels of the immunosuppressive molecules IL-10
and soluble HLA-G were associated with progression to dis-
ease and parasitological confirmation in the months following
initial serodiagnosis [23, 24]. In contrast, high levels of in-
flammatory cytokines were associated with prolonged sero-
positivity without parasitological confirmation (IL6) or even
with probable self-cure (IL8) [23]. Further evidence that im-
munosuppression due to T. b. gambiense infection is a hall-
mark of disease progression comes from two African patients
living in Europe, who, after immunosuppressive therapy, de-
veloped neurological signs and eventually were recognized as
HATcases long after they had left Africa [22, 25]. Genotyping
parasites from latent and clinical cases failed to show different
microsatellite profiles, suggesting that the host rather than the
parasite is responsible for the diversity of infection outcomes
[26]. APOL1 is a critical molecule in the interaction between
trypanosomes and humans. Two kidney disease risk coding
variants of the APOL1 gene were associated with differential
susceptibility to HAT: the G2 allele was associated with pro-
tection against T. b. rhodesiense in a Ugandan population,
whereas in Guinea, the frequency of the G1 allele was in-
creased in individuals with asymptomatic infections [27, 28].
Previous attempts to identify human genetic factors of
resistance/susceptibility to HAT have focused on candidate
gene approaches. Recently, a panel of 96 SNPs was tested in
several populations from endemic countries as part of the
TrypanoGEN project (www.trypanogen.net) [29–34].
Although significant genetic associations were observed at
the APOL1, IL6, HLAG, IL1A, and HP loci, these
associations were rather country-specific. This suggests that
resistance/susceptibility to HAT is heterogeneous with differ-
ent genes implicated in different populations depending on
history of exposure not only to a variety of pathogens but also
to the genetic diversity of trypanosomes across Africa. An
example is that the APOL1 G2 association was not replicated
in a different population from Uganda where rhodesiense
HAT is known to be more ‘chronic’ [29]. Genome-wide asso-
ciation analysis is ongoing to identify new genes with impor-
tant effects that are common across Africa. Interestingly, re-
cent studies have shown that T. b. brucei and T. b. gambiense
can reside in the skin of infected mice without detectable
parasites in the blood and that these skin-dwelling parasites
can infect tsetse flies [35]. Preliminary results indicate that
dermal trypanosomes are commonly observed in skin biopsies
not only from HAT patients but also from non-
parasitologically confirmed seropositives (manuscript in prep-
aration). The role of these skin-dwelling trypanosomes in the
life cycle within the human host, as well as their infectiousness
to tsetse flies, still needs to be elucidated.
In addition to a putative wild or domestic animal reservoir,
any undiagnosed human case of T. b. gambiense infection
may contribute to the sustained transmission of the parasite
and therefore jeopardize efforts to eliminate HAT [36].
Reasons for not being diagnosed are diverse, e.g. not showing
up during an active screening campaign or having nomeans to
reach a fixed health centre with diagnostic facilities. Also, due
to imperfect diagnostic tests, clinically and/or serologically
suspect HAT cases may remain unconfirmed by parasitologi-
cal examination tests, resulting in them not being treated and
cured.
A number of unconfirmed seropositive people were
followed up for several years and did not develop the disease
[21]. These ‘trypanotolerant’ seropositive and asymptomatic
cases are often thought to sustain transmission of the parasites
in a given focus. However, evidence that these human asymp-
tomatic cases effectively transmit the parasite to the vector is
based on very few experiments conducted decades ago [37].
In the absence of recent accurate data on the fraction of human
T. b. gambiense infections that can be considered asymptom-
atic and on their infectiousness to the vector, it remains im-
possible to correctly assess their contribution to transmission.
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Nevertheless, a study conducted in Zaïre (now D.R. Congo)
provides evidence that treatment of parasitologically non-
confirmed seropositives (not necessarily asymptomatic) can
drastically reduce the annual incidence of HAT [38].
Treatment of seropositive and asymptomatic infections can
also be beneficial to the individual person, as illustrated by a
report on the treatment of 26 parasitologically non-confirmed
seropositive people who became seronegative over time,
which was interpreted as evidence of infection before and cure
after treatment [39]. Treatment of non-confirmed seropositive
people has been proposed on several occasions but has not
been widely applied due to the toxicity of the then available
drugs. Today, the situation remains unchanged. Pentamidine is
still the recommended drug to treat T. b. gambiense patients in
first stage of the disease, when clinical symptoms are mild or
even absent. Moreover, prognostic markers for disease pro-
gression are still under investigation [24].
In view of the goals to eliminate and prevent the re-
emergence of HAT, understanding the biological mechanisms
and epidemiological role of asymptomatic T. b. gambiense
infections that remain undiagnosed or untreated is critically
important. Yet, many questions remain unanswered and de-
serve further investigation. For example: How frequent are
asymptomatic infections and what is their average duration?
How infective are they to the vector?What factors may trigger
evolution of asymptomatic infections into disease? Will the
new drugs under development be able to cure asymptomatic
infections? In order to answer these questions and to adapt
mathematical transmission models accordingly, it is necessary
to invest in improved diagnostics and investigate prognostic
markers for disease progression and treatment outcome.
Leishmaniasis
Leishmaniasis comprises a group of diseases, all caused by
parasites of the genus Leishmania and transmitted by
sandflies. Leishmania is a digenic protozoa that survives in
hostile environments, such as the flagellated ‘promastigote’
form in the midgut of the insect vector, and the ‘amastigote’
form in the phagolysosome of the mammalian macrophage.
Following infection by the sandfly vector, the parasite multi-
plies and circumvents the effect of the oxygen cascade and the
lytic action of phagolysosomes and the low pH inside the
phagolysosome. In cutaneous leishmaniasis, the Th1 response
activates such defence mechanisms and the parasite is con-
trolled. In visceral leishmaniasis, the Th2 response is triggered
and the amastigotes multiply until no more can be hosted in
the vacuole, at which point the macrophage bursts and the
parasites released invade other macrophages of the reticuloen-
dothelial system and progressively provoke enlargement of
the spleen and liver, the main symptom of visceral leishman-
iasis. The macrophage is a key immune cell persistently in-
fected by the parasite, which over one-third of macrophage
genes are activated in the presence of parasite illustrates the
complexity of this relationship [40].
Various factors determine the severity of leishmaniasis,
ranging from asymptomatic to fatal, such as the Leishmania
species, parasite virulence, and immune response of the infect-
ed individual. Although ‘virulence’ can be a simplistic ap-
proach, a didactic model stresses the role of two molecular
determinants for pathogenicity in natural Leishmania infec-
tion, the invasive/evasive determinants allowing the invasion
of the macrophage by the parasite and its survival, and mole-
cules called pathoantigens involved in tissue damage [41]. For
cases of HIV-Leishmania co-infection or during other inter-
ventions, such as chemotherapy, additional parameters should
be considered.
Leishmaniasis is a poverty-related disease, with a great
diversity of clinical presentations ranging from self-healing
cutaneous forms to the more severe visceral form (VL), which
is fatal if not treated. Although the global incidence of VL has
decreased in South Asia in recent years due to elimination
efforts [42], it remains unchanged with risk of epidemics in
Eastern Africa, and in other endemic areas such as Latin
America and Europe, the incidence of VL is growing and its
distribution is expanding because of climate change, environ-
mental transformation, and migration.
VL is caused by L. donovani and L. infantum parasites. As
mentioned, after infection, progression to clinical VL depends
on the balance between multiple factors that promote or pre-
vent the multiplication and expansion of parasites in the body:
virulence, the microbiome, factors transmitted through the
bite, nutritional status of the host and social conditions, age,
immunosuppression, concomitant diseases, etc. The complex-
ity of the response makes it difficult to predict the outcome of
the infection, but it is known that most people infected with
Leishmania remain asymptomatic. In VL endemic areas, the
ratio of asymptomatic versus active VL cases is variable: 2.4:1
in Sudan, 4:1 in Kenya, 5.6:1 in Ethiopia, between 4:1 and
17:1 in the Indian subcontinent, and 50:1 in Spain [43]. These
values reflect not only differences in the virulence of the strain
involved and the characteristics of the host but also differences
in the design of the studies and the methods used to identify
asymptomatic infections. In addition, levels of parasite trans-
mission fluctuate greatly within an endemic area, with a gra-
dient of prevalence for asymptomatic L. infantum infection
ranging from 8–12% to 35–38% [44, 45].
The various studies to determine the proportion of asymp-
tomatic individuals who progress to VL report different fig-
ures. In India, it has been described that 2 to 23% of asymp-
tomatic individuals developed symptoms within 1 year [46,
47], and this progression to VL was strongly associated with a
positive molecular test (quantitative PCR) in blood, or having
a high value for a serological test (direct agglutination test:
DAT, or rK39-ELISA) [48]. On the contrary, a positive cellu-
lar test means a very low risk of subsequent VL [48, 49]. In a
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recent cross-sectional survey done in a post-outbreak area in
Spain, 164 out of 804 (20.7%) individuals were identified as
asymptomatic by using a cellular test (whole blood stimula-
tion assay, WBA) and none of these subjects developed vis-
ceral leishmaniasis after 4 years of follow-up [45].
The term asymptomatic Leishmania infection was used for
the first time in 1974 by Pampiglione; four decades later, the
definition is still unclear. An asymptomatic person is usually
regarded as someone from an endemic area who shows an
immune response (either antibodies or a specific cellular re-
sponse) against Leishmania, or who has parasites—or parasite
DNA—in the blood, but remains healthy.
There is no single universally accepted assay to identify
asymptomatic infection. Disadvantages of using serological
tests include unsatisfactory results when parasite transmission
is low or intermittent [50] and the fact that serological markers
can revert to negative within 4 months [51]. Cell immunity
induced by Leishmania infection usually remains positive for
several years, sometimes even throughout an individual’s life.
Thus, seropositivity rates in population-based studies are con-
siderably lower than cellular reactivity rates [52]. The
leishmanin skin test (LST) has been widely used to identify
asymptomatic individuals [44, 49] but cannot currently be used
in a number of countries since no GMP leishmanin reagent has
been produced. Both the LST and the in vitro peripheral blood
mononuclear cell proliferation assay (CPA) involving soluble
Leishmania antigen (SLA) are used interchangeably since they
have good agreement (98–100%), although the latter is labori-
ous and time-consuming [53]. However, a simpler cellular test
currently in use for identifying asymptomatic people in the field
is the whole blood stimulation assay and the subsequent detec-
tion of cytokines and chemokines in stimulated plasma, which
reaches a very high specificity and sensitivity bymonitoring the
specific expression of IL-2 for L. infantum and MIG for
L. donovani in WBA, while IP-10 production has been de-
scribed as being useful for both [54]. IL-2 has been already
tested in the field [45]. Molecular methods such as PCR have
been used less often to identify asymptomatic infection due to
undetectable low parasitemia in immunocompetent individuals
(0–0.2 parasite/mL blood in asymptomatic individuals com-
pared to 32 to 188,700 parasites/mL in active VL) [55], the
difficulty of performing such analyses in the field, and the cost.
The new ready-to-use loop-mediated isothermal amplification
kit for the accurate diagnosis of leishmaniasis has not yet been
tested in the context of asymptomatic carriers. Since the results
of using a single test to determine the prevalence of asymptom-
atic subjects are highly variable and imprecise [55], and in the
absence of a gold standard, the combination of several serolog-
ical/cellular/molecular approaches to accurately estimate the
real prevalence of asymptomatic infection is recommended.
Mathematical modelling analysis has proposed that trans-
mission is mainly maintained by asymptomatically infected
hosts, on the assumption that although less infective than
cases of active VL, their huge number is a significant contrib-
utor to transmission [49, 55, 56]. Recent observational studies
stress the importance of transmission from clinical cases and
post-kala-azar dermal leishmaniasis during epidemic or inter-
epidemic periods, respectively [57]. Until now, the presence
of parasites or DNA in the peripheral blood of asymptomatic
individuals has not been correlated with positive results by
xenodiagnosis [58] (Molina et al., submitted). A recent pre-
sentation by S. Sundar at the PKDL meeting held in New
Delhi, India (30 July 2019) showed that 183 individuals with
high levels of Leishmania-specific antibodies were unable to
infect sand flies (unpublished results). Therefore, there is not
still certainty around the role of asymptomatic carriers in
maintaining transmission of leishmaniasis and it needs further
evaluation.
On the other hand, asymptomatic Leishmania infection has
been detected by PCR and LST in HIV+ patients without any
history of cutaneous or visceral leishmaniasis [59]. Cellular
tests have also been useful for detecting asymptomatic sub-
jects in a cohort of solid organ transplant recipients [60] and of
HIV+ patients with no previous leishmaniasis [61].
Years ago, R. Molina et al. confirmed the capacity for in-
fection of HIV-Leishmania-coinfected patients by xenodiag-
nosis [62]. Since then, new highly active antiretroviral thera-
pies (HAART) that help in mounting and/or maintaining a
cellular immune response might be contributing to their
asymptomatic status, which was not the case in the pre-
HAART era. Despite this, there is still a proportion of VL
cases in HIV+ patients that need secondary prophylaxis to
avoid relapse. In such cases, although they remain asymptom-
atic for VL, it has been recently demonstrated by xenodiagno-
sis that they are able to infect sandflies, meaning that this
population is still an epidemiological risk (Molina et al.,
submitted).
In summary, more research is needed to reach a consensus
on how to define ‘asymptomatic’ and on the tools to identify
carriers as the role they play in transmission may be of para-
mount importance for elimination/control programmes.
Depending on the significance of the asymptomatic popula-
tion, new chemical entities could be developed as tools for
preventive chemotherapy. In addition, research efforts will
be required to discover biomarkers and to develop field tests
for efficient validation and qualification processes.
Filariasis
Filarial nematodes that parasitize humans have developed the
ability to modulate the host immune system to assure their
long-term survival. Asymptomatic infection is hereby the best
trade-off for both organisms, avoiding pathology in the host
and ensuring parasite survival. Here we discuss the implica-
tions for bystander infections and disease epidemiology.
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Mansonella perstans infections, for example, are not asso-
ciated with a specific clinical pathology and are therefore not
considered a public health problem [63]. Similarly, although
infection with Loa loa can lead to extremely highmicrofilariae
loads and adult worms occasionally transit the eye, symptoms
are not frequent in endemic populations [64]. Infections with
the filarial nematodes Wuchereria bancrofti, Brugia malayi,
Brugia timori, orOnchocerca volvulus, however, have gained
more attention as clinical manifestations may develop.
Whereas W. bancrofti and Brugia spp. cause lymphatic filari-
asis that can involve lymphoedema of the extremities
(elephantiasis) or the scrotum (hydrocele), infection with
O. volvulus causes onchocerciasis that can result in vision
impairment, blindness, or severe dermatitis [65]. However,
lymphatic filariasis and onchocerciasis infections do not nec-
essarily cause pathology. Approximately one-third of lym-
phatic filariasis patients develop oedema in the limb and/or
scrotum [66] and 30–50% of onchocerciasis patients develop
dermatitis, with ~ 1% of the patients developing its most se-
vere form, also called hyperreactive onchocerciasis or sowda
[67].
Clinical symptoms and microfilaremia, the presence of the
filarial progeny (microfilariae) that is required for the trans-
mission of the disease, are closely connected to the host’s
immune response. As is common for nematode infections,
filariae are strong inducers of type 2 immune responses, char-
acterized by eosinophilia, an increased number of innate type
2 lymphocytes, and increased production of type 2 cytokines,
and the expansion of IgE antibodies [68]. All of these are
important factors for defence against the parasite and are also
responsible for the development of clinical symptoms. They
are most pronounced, for example, in onchocerciasis patients
that develop severe skin dermatitis, which show the strongest
Th17 and Th2 immune profiles [67, 69]. Such inflammatory
responses are, however, also linked with protective immune
responses against the filariae, as sowda patients are often
amicrofilaremic [67]. In lymphatic filariasis, around 50% of
patients develop microfilaremia. Peripheral blood mononucle-
ar cells (PBMCs) from amicrofilaremic patients have been
shown to release more parasite-specific IL-5 and non-
specific IL-17 and pro-inflammatory cytokines [70], indicat-
ing that increased immune responses are mediating protective
immune responses against the filariae; however, this also co-
incides with the development of pathology. Amicrofilaremic
infections are also common for L. loa infections [64] and
probably also exist for infections with M. perstans, although
this has not been proven yet.
Filariae can establish an antiinflammatorymilieu over time,
which leads to the expansion of regulatory cell types such as
alternatively activated macrophages or regulatory T cells, in-
creased production of antiinflammatory cytokines, immuno-
suppressive IgG4, and development of T cell anergy [68, 71].
Regulatory immune responses have evolved to shut down
antiparasitic immune responses, facilitating parasite survival,
and are associated with asymptomatic filarial infections. Such
a suppressive environment can also affect bystander immune
responses and therefore alter the outcome of co-infections or
immune responses that may otherwise lead to autoimmunity
or metabolic disease [68, 72, 73].
Observational studies of co-infections with Plasmodium in
humans provide evidence that microfilariae-positive infec-
tions with filarial nematodes are associated with suppressed
Plasmodium-specific immune responses and with increased
Plasmodium-specific regulatory responses [74, 75].
Similarly,W. bancrofti andM. perstans infections were shown
to reduce pro-inflammatory cytokine and chemokine re-
sponses during clinical malaria, although clinical signs and
symptoms of malaria were not significantly altered, except
for increased haemoglobin levels in filariae-infected patients
[76]. Similarly, filariasis patients were not associated with
changes in the severity of malaria infection.
A similar picture is given for immune responses during
latent infections with Mycobacterium tuberculosis (MTB),
where PBMCs from patients with active lymphatic filariasis
had impaired MTB-specific immune responses, but an in-
creased expression of inhibitory molecules [77]. As IFNγ-
driven type 1 immune responses are thought to mediate pro-
tection against MTB, these results indicate that filarial infec-
tion impairs those protective responses during MTB [77].
Nevertheless, results from human studies and animal models
are often contraindicatory, as, e.g. co-infections of humans
with helminths (including filariae) were not associated with
the progression from latent to active MTB or an increased
MTB pathology [78]. Indeed, suppression of exacerbated
pro-inflammatory immune responses by chronic filarial infec-
tion may even provide a beneficial impact, as has been indi-
cated by experimental and human sepsis studies [73].
Furthermore, infections with W. bancrofti were identified
as a risk factor for acquiring HIV infection [79]. While exper-
imental infections with intestinal helminths have been shown
to impair protective immune responses and lead to an in-
creased viral load during co-infection with influenza or mu-
rine norovirus [80], a reduction of HIV titres was not observed
after antifilarial therapy inW. bancrofti–infected patients [81].
The above-mentioned examples demonstrate that filarial
infections modulate protective immune responses against oth-
er pathogens and may thereby alter clinical pathology.
Current control strategies for onchocerciasis and lymphatic
filariasis are based on preventive chemotherapy programmes
administered in mapped areas to the at-risk population as a
whole (MDA programmes) regardless of whether the individ-
ual is infected. Programmes directed by the World Health
Organization (WHO) for the treatment and control of filarial
disease have been in place for over 40 years and have had a
tremendous beneficial impact on public health due to the
availability and safety of donated anthelmintic drugs. As
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MDA targets the population at risk rather than identifying and
treating infected individuals, these approaches reach both
asymptomatic and symptomatic patients infected with oncho-
cerciasis and lymphatic filariasis.
Limited knowledge about the biology, transmission, clini-
cal aspects of the disease, and impact on public health is cur-
rently available for asymptomatic patients infected with filar-
ial nematodes. It has become clear that immunomodulation
during asymptomatic filarial infection can impact immune
responses during co-infections, but the clinical impact is less
well described. Thus, more research is required to understand
the impact of filarial infection on the development of MTB
and malaria pathology and whether a co-existing filarial infec-
tion alters the risk of reactivation of latent MTB or accelerates
the development of AIDS. Given that filarial infections also
impair immune responses to vaccines [82], it can be
hypothesised that asymptomatic filarial infections are of major
importance for several infectious diseases and more research
is required to pinpoint their exact role. Furthermore, it is well
described that filariae produce more offspring in immunosup-
pressed patients and thus contribute to ongoing transmission.
While amicrofilaremic filariasis patients are not per se
asymptomatic and do not contribute to the transmission of
filarial disease, there is also a need to investigate these patients
in more detai l . I t is not known whether chronic
amicrofilaremic patients can develop microfilaremia later on
and thus contribute to the transmission of filarial disease.
Since these patients may be missed after the closure of
MDA programmes, they present a potential risk factor for
re-emerging transmission. Furthermore, diagnostic tools to
specifically detect L. loa and M. perstans adult worm infec-
tions in a microfilariae-independent manner are required to
identify amicrofilaremic patients, which will allow for the
analysis of their contribution to co-infections or as potential
reservoir hosts for the transmission of the disease.
Malaria
Malaria is a preventable and curable disease, caused by para-
sites of the Plasmodium genus. Across the globe, 3.3 billion
people are at risk of malaria, with an estimated 219 million
cases and 435,000 deaths in 87 countries in 2017. Global
malaria incidence declined by 18% between 2010 and 2017
and was achieved by roll-out of vector control interventions
and massive distribution of rapid diagnostics and effective
treatment [83]. There has been no further decline in the past
3 years, but rather, the ten highest burden countries in Africa
have once again reported increases in the number of cases
[83]. Following these initial successes in malaria control, the
focus of antimalarial interventions has shifted in many areas
from clinical case management to transmission control. Some
endemic countries already have achieved, or are aiming to
achieve, elimination [84].
Knowledge about carriers of asymptomatic infection is in-
creasingly important for guidingmalaria control interventions,
particularly in settings of low endemicity, because these indi-
viduals mostly remain unnoticed and thus represent an impor-
tant silent reservoir for onward transmission of Plasmodium
parasites to the respective Anopheles vectors. Improved diag-
nostic techniques have revealed an unexpected large reservoir
of asymptomatic infections. In recent years, convincing evi-
dence on the contribution of asymptomatic infections to on-
ward transmission has become available. Malaria transmis-
sion models show that asymptomatic infections, including
low-density infections, contribute to ongoing malaria trans-
mission because of the high proportion in the population com-
pared to high density clinical cases [85, 86]. Data on infectiv-
ity available so far suggest that light microscopy (LM) and
rapid diagnostic tests (RDT) are not sufficiently sensitive to
detect the asymptomatic reservoir and that diagnostic methods
applied in the field should be adjusted to more sensitive de-
tection for low-density infections [87].
Key public health interventions aimed at asymptomatic par-
asite reservoirs are drug-mediated strategies, namely (1) mass
drug administration (MDA) in an area of transmission irrespec-
tive of infection and symptoms; (2) mass screening and treat-
ment with intensive active case detection; (3) intermittent pre-
ventive treatment—with repeated treatment of high-risk
groups. These approaches have been adopted at different scales
and with variable degrees of success, but their combined use is
considered an important component of malaria elimination and
eradication [88]. Molecular-epidemiological data are very use-
ful for identifying pockets of transmission, particularly in areas
of declining malaria transmission, and to guide the choice of
control interventions. Molecular tools also provide strategies to
validate interventions, but the successful implementation of
active case detection is highly dependable on the sensitivity
of the diagnostics employed.
Asymptomatic malaria infections and symptomatic clinical
episodes have different parasite densities, and thus, the ease of
detection is dependent on the diagnostic method for each
form. Clinical episodes are generally detectable by blood slide
LM or RDT. Differentiation of clinical malaria and non-
malaria fevers is complicated by the prevalence of low-
density Plasmodium sp. infections. Diagnosis of bystander
malaria infections may obscure viral or bacterial causes of
fever and prevent adequate treatment. RDTs are now widely
used as the sole diagnostic for management of clinical malaria.
It is safe to withhold antimalarial treatment in infants and
young children in all fever cases that are negative by RDT,
as has been shown in different endemic settings, including an
area with high P. vivax prevalence [89, 90]. Such RDT-based
treatment strategies have improved the rational use of antima-
larial drugs.
Some, but not all, asymptomatic infections can be diag-
nosed by LM or RDT; however, most malaria infections are
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missed if nomolecular diagnostic test is used. Prevalence rates
in the community differ substantially depending on the diag-
nostics applied. The detection limit of LM and molecular as-
says differ by several orders of magnitude, i.e. LM and RDT
have a detection limit in routine settings of 100–200 parasites/
μL blood on average [83], whereas molecular assays can
reach a sensitivity as high as 0.03 parasites/μL blood [91],
representing an over 1000-fold improvement.
The proportion of submicroscopic Plasmodium falciparum
infections, i.e. parasitaemia only detectable by PCR, depends
on transmission intensity: in regions of low endemicity, the
proportion of all P. falciparum infections that are submicro-
scopic may be as high as 80%. Meta-analyses on global data
sets compared prevalence rates determined by PCR versus
LM and demonstrated that the proportion of submicroscopic
P. falciparum infections substantially increases with declining
malaria transmission intensity [92, 93]. This trend was con-
firmed in the past few years by numerous molecular-
epidemiological studies [94, 95]. Furthermore, a recent study
in Zambia, presenting a pre-elimination setting, showed that
almost half of all infections remained undetected by RDT
[96].
Two meta-analyses that investigated the relationship of
P. vivax prevalence by LM versus PCR revealed similar trends
as found for P. falciparum [97, 98]. Both systematic reviews
analysed cross-sectional studies from Asia, South America,
and the South Pacific with concordant results: high prevalence
of submicroscopic P. vivax infections and PCR detecting on
average 67% more infections than LM. In addition, the pro-
portion of submicroscopic infections was higher in areas of
low transmission [97]. Generally, P. vivax densities are
several-fold lower than those of P. falciparum [99]. This rep-
resents an additional challenge for P. vivax detection. Ultra-
sensitive molecular diagnostic assays for P. vivax address this
limitation by targeting mitochondrial DNA, which is present
in a higher number of copies per cell [87, 100].
To increase diagnostic sensitivity for malaria parasites,
molecular-epidemiological studies processed large volumes
of venous blood or used ultra-sensitive molecular assays that
target multiple genomic copies of the molecular marker per
cell [101, 102]. A recent study conducted in Papua New
Guinea, where P. falciparum and P. vivax prevalence is equal-
ly high, revealed an unexpected high prevalence of asymp-
tomatic sub-microscopic infections, a large proportion (up to
50%) of which was not detected by standard molecular diag-
nostics (18S rRNAquantitative PCR) using finger-prick blood
volumes [91]. This study showed that ultra-low-density ma-
laria infections do not accumulate in certain demographic
pockets, thus removing the need to specifically target certain
population subgroups if such low-density infections are to be
investigated. The diagnostic sensitivity of highly sensitive as-
says of finger prick blood samples was sufficient for detecting
86% and 91% of the individuals in the community who carry
P. falciparum and P. vivax transmission stages (gametocytes)
[91]. Thus, analysis of larger blood volumes revealed a large
pool of ultra-low-density P. falciparum andP. vivax infections,
which are unlikely to be transmitted. Additionally, current
RDTs, assessed in parallel, cannot replace molecular diagnos-
tics for identifying potential sources of P. falciparum
transmission.
Solid knowledge now exists on the unexpected high prev-
alence of asymptomatic infections that are below the micro-
scopic detection threshold and even below the limit of detec-
tion of standard molecular techniques. This extensive submi-
croscopic reservoir has major consequences for malaria sur-
veillance activities, in particular for pre-elimination settings,
where most infections are below the detection limit of LM and
RDTs and thus would escape diagnosis during malaria control
interventions.
Diagnosis of low-density infections currently does not play
a role in case management of clinical malaria; however, highly
sensitive molecular detection is highly relevant for epidemio-
logical studies, e.g. trials of antimalarial interventions, map-
ping parasite foci, and determining age-dependent risk factors
of infection.
Discussion and conclusions
The concept ‘asymptomatic’ needs careful definition as it
describes a dynamic process. At each stage, the role of the
asymptomatic carrier is different. When a human host is
infected with a parasite, the host immune response initiates
a cascade of events that are specific to the invader and can
precipitate three kinds of response: (1) the parasite is elim-
inated and the infection is overcome; (2) the parasite es-
capes the host response and invades the tissues, leading to
clinically relevant disease preceeded by a premanifest
(‘prepatent’) period in which the parasite and its effect(s)
on the host are detectable using appropriate methodolo-
gies; and (3) the parasite becomes resistant to the host
response and enters a chronic phase of disease where both
host and parasite co-exist. However, such co-existance is
not without consequences, possibly leading to progressive
(silent) organ damage and, in addition, may contribute to
parasite transmission to new hosts. Although our knowl-
edge of parasitic diseases is considerable, a number of
questions pertaining to the asymptomatic period remain
unresolved, summarizied in Box 1.
Evidence for the role of asymptomatics as reservoirs for
infection and re-emergence and, possibly, new outbreaks is
specific to each disease. The role of asymptomatic carriers is
probably best described for malaria and Chagas disease, while
it is less well understood for lymphatic filariasis,
onchocerciais, leishmaniasis, and HAT.
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Chagas disease
Asymptomatic carriers of T. cruzi are impacted at both per-
sonal and societal levels and affect transmission dynamics.
Unlike malaria, the course of Chagas disease in asymptomatic
infection is unpredictable, ranging from possible sudden death
in the acute phase to a chronic form of disease persisting for
decades with few demonstrable clinical symptoms before full
manifestation of life-threatening cardiac and digestive disease.
The possibility of chronic disease has a psychological impact
on patients and family groups and a social impact due to
stigmatization and exclusion from potential sources of work.
The beneficial impact of antiparasitic treatment for asymptom-
atic carriers is not widely discussed; those who do not receive
treatment have detectable parasitemia cycles, can be a poten-
tial reservoir to vectors, are a reservoir for congenital trans-
mission, and act as a potential source for contamination of
blood banks when monitoring is not carried out. Early diag-
nosis and timely antiparasitic treatment are necessary for a
favourable impact at individual, social, and epidemiological
levels. Diagnosis and treatment of asymptomatic children will
result in generations without infection and in women of child-
bearing age will prevent congenital transmission. The role of
asymptomatic individuals in Chagas disease is actively inves-
tigated in the research community and the findings applied to
disease management.
Human African trypanosomiasis
Although the existence of human asymptomatic infections
with Trypanosoma brucei is well documented, their role in
transmission remains unknown. Only recently have some re-
search groups, including transmission modellers, prioritized
this phenomenon and focused investigations into the underly-
ing mechanism of trypanotolerance, relative frequency of
asymptomatics among infected persons, and infectivity poten-
tial of trypanotolerant individuals to tsetse flies. It is unlikely
that the existence of asymptomatic carriers would compro-
mise the HAT elimination goal, as current strategies targeting
patients have successfully led to a drastic decrease of disease
prevalence in the last 10 years. Nevertheless, if the role of
asymptomatics as a reservoir is confirmed, new strategies will
be needed to either sustain elimination or interrupt transmis-
sion. In the absence of established prognostic markers for
disease progression and in view of HAT elimination, health
workers are still confronted with the dilemma of whether or
not to treat asymptomatic carriers. This dilemma can only be
resolved if new drugs with high benefit/ safety ratios are avail-
able for treating otherwise healthy individuals. In the mean-
time, vector control will continue to be an important tool to
control residual transmission of T. b. gambiense in endemic
populations.
Leishmaniasis
Most people infected by Leishmania species remain asymp-
tomatic and, although they are not thought to play a significant
role in transmission, more xenodiagnosis studies are needed to
elucidate their role as a reservoir for outbreaks, a frequently
observed feature of leishmaniasis. Additionally, biomarkers
for identifying the underlying cause(s) for progression from
infection to disease would be valuable for epidemiological
studies and prevention in endemic areas. Importantly, asymp-
tomatic individuals that become candidates for a programmed
immunosuppression for organ transplantation or therapy for
autoimmune diseases may require follow-up and surveillance
for several years. HIV-positive individuals with asymptomatic
infection should be considered potential leishmaniasis cases
and therefore suitable for treatment, even though the cellular
immune response to the parasite can still be positive. Finally,
HIV-positive patients who have been treated for VL and re-
main asymptomatic but with confirmed capability to infect
sandflies have to be considered as ‘spreaders’ and thus should
be encouraged to use physical and chemical barriers to avoid
being bitten by sandflies. Monitoring the CD4 count and PCR
in blood before, during, and after treatment is mandatory.
Filariasis
Current control strategies for lymphatic filariasis and oncho-
cerciasis use MDA-based approaches, treating the population
as a whole, including treatment of patients who are symptom-
atic, asymptomatic carriers, and persons at risk in endemic
areas. However, the contribution of asymptomatic carriers
(microfilaremic or amicrofilaremic) to disease transmission
is unknown. Following the closure of MDA programmes,
Box 1 A number of questions pertaining to the asymptomatic period
The concept of ‘asymptomatics’ is of enormous importance and has
become a major topic for research. Frequent questions in the research
of asymptomatic carriers are:
• Are asymptomatic individuals able to transmit the parasite despite the
low burden of circulating parasites?
• Is an asymptomatic carrier the same as an asymptomatic individual, as a
reservoir for transmission?
• Are people carrying a parasite infectious at any moment despite the
enhanced immune vigilance of the host, and does this vary across the
time of infection?
• Can asymptomatic carriers be detected with conventional methods
(microscopy, serology, PCR)?
• With the current tools, it is possible to distinguish between an
asymptomatic carrier and one in the prepatent period?
• Among asymptomatic carriers, are there super-spreaders?
• Are scientists using the same concepts and terminology when referring
to asymptomatic carriers?
•Are risk factors that trigger the change from the asymptomatic condition
towards clinically impactful disease the same as those that accelerate
the prepatent period to florid disease?
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amicrofilaremic carriers are likely to be missed, presenting a
potential risk for reemergence of disease. Furthermore, the
immunomodulation that occurs in asymptomatic filariasis pa-
tients impacts co-infections, vaccines, and metabolic and au-
toimmune responses and therefore presents an often neglected
variable in this context.
Malaria
Asymptomatic individuals carrying malarial parasites have
been well characterized, and their role in disease propagation
is better understood than for the parasitic infections discussed
above. Transmission models show that asymptomatic and
low-density infections contribute to transmission, although
current diagnostic tests based on light microscopy and rapid
diagnostic tests may not be sensitive enough to detect asymp-
tomatic individuals in the field setting, with prevalence rates in
the community differing substantially depending on the diag-
nostic applied. There is a clear need for improved diagnostics
to support elimination efforts, as well as more research on the
relative cost-effectiveness and operational feasibility of drug-
mediated health interventions aimed at asymptomatic parasite
reservoirs. Evidence-based guidance on optimummethods for
implementing MDA programmes, promoting community en-
gagement and compliance with treatment, and evaluating the
effectiveness of MDA programmes is needed. Modelling ap-
proaches can inform the optimum method for administering
MDA in different epidemiological circumstances and help
predict its likely impact.
In malaria and Chagas disease, asymptomatic carriers are
clearly acknowledged as a significant risk to control and elim-
ination programs because of their role in transmission and
outbreaks. Such clear examples of the role of asymptomatic
individuals in evolving disease emphasizes the need for a
better understanding of the contribution of asymptomatic in-
dividuals in filariasis, HAT, and leishmaniasis, and the possi-
ble impact on elimination programs. This is of paramount
importance given that HAT in Africa and leishmaniasis in
Asia are diseases approaching the elimination target in 2020.
In addition, surveillance is required; as in past decades, elim-
ination targets have been nearly achieved only to fall to new
outbreaks. More research is needed on asymptomatic individ-
uals to enable the control and elimination of such diseases in
the future. DNDi has focussed on innovating easy-to-use, oral
drugs with potential for short duration of therapy to facilitate
cure of disease in clinically manifest patients. Hence, it is
conceivable that safe, effective therapies can be delivered for
treatment of asymptomatic individuals, should they be dem-
onstrated to play a key role in disease transmission or out-
breaks. For example, DNDi has already achieved change in
the treatment of HAT with the introduction of NECT in 2009
and the first oral therapy, fexinidazole, in 2019. Should
asymptomatic individuals prove to be a reservoir for renewed
infections, then acoziborole, a single-dose oral drug with a
good safety profile in clinical testing, may have utillity in
asymptomatic individuals and populations.
In conclusion, the future is much brighter than at the turn of
the century. Drugs intended to be patient-adapted, orally ac-
tive, and with short treatment regimens are in clinical testing
for both leishmanisis and Chagas disease, opening up the pos-
sibility of a future where all segments of the patient disease
population, both clinically manifest and asymptomatic, can be
treated effectively and safely.
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